Tonix Pharma announces Breakthrough Therapy designation remains in effect for Tonmya®
Tonix Pharmaceuticals announced the FDA has withdrawn its previously issued Breakthrough Therapy Designation Rescind letter and confirmed that the Breakthrough Therapy designation granted in December 2016 remains in effect for Tonmya (cyclobenzaprine HCl sublingual tablets) for treatment of PTSD. April 22, 2019